BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18316568)

  • 1. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
    Attar EC; De Angelo DJ; Supko JG; D'Amato F; Zahrieh D; Sirulnik A; Wadleigh M; Ballen KK; McAfee S; Miller KB; Levine J; Galinsky I; Trehu EG; Schenkein D; Neuberg D; Stone RM; Amrein PC
    Clin Cancer Res; 2008 Mar; 14(5):1446-54. PubMed ID: 18316568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
    Horton TM; Perentesis JP; Gamis AS; Alonzo TA; Gerbing RB; Ballard J; Adlard K; Howard DS; Smith FO; Jenkins G; Kelder A; Schuurhuis GJ; Moscow JA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1754-60. PubMed ID: 24976003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
    Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
    Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
    Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
    Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
    Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
    Walker AR; Klisovic RB; Garzon R; Schaaf LJ; Humphries K; Devine SM; Byrd JC; Grever MR; Marcucci G; Blum W
    Leuk Lymphoma; 2014 Jun; 55(6):1304-8. PubMed ID: 23952243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
    Ravandi F; Cortes JE; Jones D; Faderl S; Garcia-Manero G; Konopleva MY; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce SR; Brandt M; Byrd A; Bekele BN; Pratz K; Luthra R; Levis M; Andreeff M; Kantarjian HM
    J Clin Oncol; 2010 Apr; 28(11):1856-62. PubMed ID: 20212254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
    Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
    Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
    Mayer K; Hahn-Ast C; Schwab K; Schmidt-Wolf IGH; Brossart P; Glasmacher A; von Lilienfeld-Toal M
    Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.